公开(公告)号：US20140200184A1

公开(公告)日：2014-07-17

申请号：US14166264

申请日：2014-01-28

申请人： YALE UNIVERSITY

发明人： Jack A. Elias ,  Chirag R. Parikh ,  Lloyd G. Cantley

IPC分类号： G01N33/68 ,  A61K38/47 ,  C12Q1/68

CPC分类号： A61K38/47 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6887 ,  G01N33/6893 ,  G01N2333/924 ,  G01N2800/347 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

摘要： The present invention provides compositions and methods for the detection, treatment, and prevention of a kidney injury. The invention relates to the discovery that chitinase 3-like 1/Brp-39/YKL-40 serves as both a biomarker for the degree of kidney injury and a critical mediator of a reparative response in the kidney.

摘要翻译： 本发明提供了用于检测，治疗和预防肾损伤的组合物和方法。 本发明涉及几丁质酶3样1 / Brp-39 / YKL-40用作肾损伤程度的生物标志物和肾脏修复反应的关键介质的发现。

公开(公告)号：US20140178884A1

公开(公告)日：2014-06-26

申请号：US14118502

申请日：2012-05-22

申请人： David Aucoin ,  Thomas R. Kozel ,  Sindy Chaves

发明人： David Aucoin ,  Thomas R. Kozel ,  Sindy Chaves

IPC分类号： G01N33/569

CPC分类号： G01N33/56961 ,  G01N33/6893 ,  G01N2333/38 ,  G01N2800/52 ,  G01N2800/54

摘要： Disclosed herein are methods of diagnosing, monitoring and treating an Aspergillus species-associated condition, such as Aspergillus fumigatus (Af)-associated condition, including aspergillosis, such as invasive aspergillosis (IA). Methods for diagnosing and/or monitoring an Aspergillus species-associated condition, such as IA are provided. Also disclosed are point-of-care immunoassays that can be used to diagnose or monitor the efficacy of an Aspergillus-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by an Aspergillus species, such as Af.

摘要翻译： 本文公开了诊断，监测和治疗曲霉属物种相关病症的方法，例如烟曲霉（Af）相关病症，包括曲霉病，例如侵袭性曲霉病（IA）。 提供了用于诊断和/或监测曲霉属物种相关病症如IA的方法。 还公开了可用于诊断或监测曲霉相关病症治疗的功效的点护理免疫测定。 这些免疫测定也可以用于快速诊断由曲霉属物种如Af产生的感染。

公开(公告)号：US08753892B2

公开(公告)日：2014-06-17

申请号：US13320283

申请日：2010-05-11

申请人： Ralf Hoffmann ,  Miles Douglas Houslay ,  David James Peter Henderson

发明人： Ralf Hoffmann ,  Miles Douglas Houslay ,  David James Peter Henderson

IPC分类号： G01N33/68

CPC分类号： G01N33/68 ,  C12N9/16 ,  C12N15/1137 ,  C12N15/115 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/16 ,  C12Q1/44 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Y301/04017 ,  G01N33/57434 ,  G01N2333/916 ,  G01N2800/52 ,  G01N2800/54 ,  Y10S436/813

摘要： The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer, as well as a pharmaceutical composition comprising a compound directly stimulating or modulating the activity of PDE4D7, a compound indirectly stimulating or modulating the activity of PDE4D7, the PDE4D7 protein or a biologically active equivalent thereof, a nucleic acid encoding and expressing PDE4D7, a miRNA inhibitor specific for PDE4D7 miRNAs, a demethylation agent and/or a phosphodiesterase displacement factor.

摘要翻译： 本发明涉及用作前列腺癌标志物的磷酸二酯酶4D7（PDE4D7），以及使用PDE4D7作为诊断，检测，监测或预测前列腺癌或前列腺癌进展的标志物。 本发明还涉及用于诊断，检测，监测或预测前列腺癌或前列腺癌进展的组合物，相应的方法和免疫测定，用于诊断，监测或预测激素抵抗性前列腺癌与激素敏感前列腺的方法 癌症，相应的免疫测定，数据采集方法，用于诊断，检测，监测或预测前列腺癌的免疫测定或前列腺癌的进展，鉴定个体对前列腺癌治疗的资格的方法，用于分层个体的免疫测定 或具有前列腺癌疾病的个体队列，用于分层患有前列腺癌的个体的免疫测定，以及包含直接刺激或调节PDE4D7活性的化合物的药物组合物，间接刺激或调节PDE4D7活性的化合物 PDE4D7蛋白或生物学 其活性成分，编码并表达PDE4D7的核酸，PDE4D7 miRNA特异性的miRNA抑制剂，去甲基化剂和/或磷酸二酯酶置换因子。

公开(公告)号：US20140099300A1

公开(公告)日：2014-04-10

申请号：US14044792

申请日：2013-10-02

申请人： NESTEC S.A.

发明人： Phillip Kim ,  Sharat Singh

IPC分类号： G01N33/68 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/517

CPC分类号： G01N33/6893 ,  A61K31/517 ,  A61K31/5377 ,  A61K45/06 ,  G01N33/57446 ,  G01N2333/71 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

摘要： The present invention provides assays and methods for predicting the post-operative survival of a subject having an early stage gastric cancer after tumor surgery. The present invention also provides methods for treating a subject having an early stage gastric cancer by administering a combination therapy tailored to the signal transduction biomarkers that are activated in the cancer. In particular embodiments, the methods of the invention rely on the detection of the activation state or level of a specific combination of signal transducer analytes in a cancer cell obtained from the subject. Thus, the methods of the invention are particularly useful for predicting the survival or prognosis of a subject having an early stage gastric cancer and for guiding both pre- and post-operative treatment decisions by identifying subjects who would benefit from combination therapy as opposed to monotherapy.

摘要翻译： 本发明提供了用于预测肿瘤手术后具有早期胃癌的受试者的术后存活的测定和方法。 本发明还提供了通过施用针对在癌症中被激活的信号转导生物标志物进行定制的组合疗法来治疗患有早期胃癌的受试者的方法。 在具体实施方案中，本发明的方法依赖于从受试者获得的癌细胞中检测信号转导分析物的特定组合的活化状态或水平。 因此，本发明的方法对于预测具有早期胃癌的受试者的存活或预后特别有用，并且通过鉴定受益于组合治疗的受试者而不是单一疗法来指导术前和术后治疗决定 。

公开(公告)号：US20140073527A1

公开(公告)日：2014-03-13

申请号：US14022468

申请日：2013-09-10

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： Paula Jill Hurley ,  Edward M. Schaeffer

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57434 ,  G01N33/57492 ,  G01N2800/54

摘要： The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer in a patient. In a specific embodiment, a method for determining a likelihood of prostate cancer recurrence in a patient following prostectomy comprises the steps of (a) obtaining a biological sample from the patient; (b) subjecting the sample to an assay for detecting SPARCL1 expression; and (c) determining that prostate cancer is likely to recur if SPARCL1 expression is decreased relative to a reference non-prostate cancer sample.

摘要翻译： 本发明涉及癌症领域。 更具体地，本发明提供了可用于评估患者中前列腺癌的方法和组合物。 在具体实施方案中，用于确定前列腺切除术后患者中前列腺癌复发的可能性的方法包括以下步骤：（a）从患者获得生物样品; （b）对样品进行检测以检测SPARCL1表达; 和（c）如果SPARCL1表达相对于参照非前列腺癌样品降低，则确定前列腺癌可能复发。

公开(公告)号：US20130310267A1

公开(公告)日：2013-11-21

申请号：US13841887

申请日：2013-03-15

申请人： Mark D. GUSTAVSON ,  Jason CHRISTIANSEN

发明人： Mark D. GUSTAVSON ,  Jason CHRISTIANSEN

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/57484 ,  G01N33/74 ,  G01N33/743 ,  G01N2800/50 ,  G01N2800/54

摘要： The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient.

摘要翻译： 本技术一般涉及确定癌症患者疾病复发的风险。 特别地，这种确定复发风险的方法包括利用选自雌激素受体（ER），孕酮受体（PR），人表皮生长因子受体2（HER2）和Ki-67（HER2）的生物标志物表达水平的标准化定量评估 Ki67）在患者的肿瘤中以确定复发的风险，从而允许看护者确定患者的最佳治疗过程。

公开(公告)号：US08583588B2

公开(公告)日：2013-11-12

申请号：US13074745

申请日：2011-03-29

申请人： Masaki Shibayama ,  Hideki Ishihara ,  Keigo Gohda ,  Satoshi Nakayama ,  Tadashi Kiniwa

发明人： Masaki Shibayama ,  Hideki Ishihara ,  Keigo Gohda ,  Satoshi Nakayama ,  Tadashi Kiniwa

IPC分类号： G06F17/00 ,  C12Q1/68 ,  G06F19/18

CPC分类号： G06F19/18 ,  G01N33/57496 ,  G01N2800/54

摘要： A method for judging a risk of cancer recurrence comprising: acquiring an activity value and expression level of a first cyclin dependent kinase (CDK) of a cell contained in tissues extracted from cancer patients, an activity value and expression level of a second CDK, and a number of Ki67-expressing cells or an expression level of Ki67; and judging a risk of cancer recurrence based on the acquired activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and a percentage of Ki67-expressing cells or the expression level of Ki67. A computer program product and a computer system are also disclosed.

摘要翻译： 一种判断癌症复发风险的方法，包括：获得癌症患者提取的组织中含有的细胞的第一细胞周期蛋白依赖性激酶（CDK）的活性值和表达水平，第二CDK的活性值和表达水平，以及 多个Ki67表达细胞或Ki67表达水平; 根据获得的第一CDK的活性值和表达水平，第二CDK的活性值和表达量以及Ki67表达细胞的百分比或Ki67的表达水平来判断癌症复发的风险。 还公开了一种计算机程序产品和计算机系统。

公开(公告)号：US20130171642A1

公开(公告)日：2013-07-04

申请号：US13729225

申请日：2012-12-28

申请人： Gary Pestano ,  Ryan Dittamore ,  Karl Garsha ,  Michael Otter ,  Chol Steven Yun ,  Alexandra Dea Nagy

发明人： Gary Pestano ,  Ryan Dittamore ,  Karl Garsha ,  Michael Otter ,  Chol Steven Yun ,  Alexandra Dea Nagy

IPC分类号： C12Q1/68

CPC分类号： G01N33/57434 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

摘要： The disclosure provides methods for automated characterization of circulating tumor cells (CTCs), for example using automated tissue strainers. In specific examples, such methods permit characterizing a prostate cancer sample by simultaneously or contemporaneously detecting ERG rearrangements and PTEN deletions in the same CTC. Also provided are kits that can be used with such methods.

摘要翻译： 本公开提供了用于自动表征循环肿瘤细胞（CTC）的方法，例如使用自动组织过滤器。 在具体实例中，这种方法允许通过同时或同时检测相同CTC中的ERG重排和PTEN缺失来表征前列腺癌样品。 还提供了可以与这些方法一起使用的试剂盒。

公开(公告)号：US20130137102A1

公开(公告)日：2013-05-30

申请号：US13759519

申请日：2013-02-05

申请人： TUFTS MEDICAL CENTER, INC.

发明人： Rachel J. Buchsbaum

IPC分类号： G01N33/68 ,  C12Q1/02 ,  C12Q1/68

CPC分类号： G01N33/6872 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2800/54 ,  G01N2800/56

摘要： Methods and kits for evaluating invasive potential and metastatic potential of cancers by assessing Tiam1 expression levels in fibroblasts in the microenvironments surrounding tumors are provided.

摘要翻译： 提供了通过评估肿瘤周围微环境中成纤维细胞中Tiam1表达水平来评估癌症侵袭潜力和转移潜力的方法和试剂盒。

公开(公告)号：US20130072395A1

公开(公告)日：2013-03-21

申请号：US13658314

申请日：2012-10-23

申请人： University of South Florida

发明人： Hong-Gang Wang ,  Domenico Coppola

IPC分类号： C40B30/06 ,  G01N33/574

CPC分类号： G01N33/574 ,  G01N33/57419 ,  G01N2800/52 ,  G01N2800/54

摘要： The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition.

摘要翻译： 本发明包括通过将BIF-1的样品水平与参考物进行比较来检测肿瘤状况的存在的方法，其中样品中低水平的BIF-1与肿瘤状况的存在相关。 另一种方法包括通过将Bif-1的样品水平确定为Bif-1的参考水平来确定复发，肿瘤复发和/或转移的风险，其中低样本水平与复发，复发和/或转移的可能性相关 。 另一种方法包括检测前肿瘤状况如前列腺上皮内瘤变的存在。 该方法包括测量样品中Bif-1的水平，并将样品中Bif-1的水平与Bif-1的参考水平进行比较。 样本中高水平的Bif-1与肿瘤前病变的存在相关。